BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 27864890)

  • 1. Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1-mutated and PTEN-wild-type triple-negative breast cancer cells.
    El Guerrab A; Bamdad M; Bignon YJ; Penault-Llorca F; Aubel C
    Mol Carcinog; 2017 May; 56(5):1383-1394. PubMed ID: 27864890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer.
    El Guerrab A; Bamdad M; Kwiatkowski F; Bignon YJ; Penault-Llorca F; Aubel C
    Oncotarget; 2016 Nov; 7(45):73618-73637. PubMed ID: 27655662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
    Kim EM; Mueller K; Gartner E; Boerner J
    J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
    Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
    Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
    [No Abstract]   [Full Text] [Related]  

  • 6. EGFR and MEK Blockade in Triple Negative Breast Cancer Cells.
    Maiello MR; D'Alessio A; Bevilacqua S; Gallo M; Normanno N; De Luca A
    J Cell Biochem; 2015 Dec; 116(12):2778-85. PubMed ID: 25959272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
    Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
    Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
    Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
    Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Half-Chain Cetuximab Nanoconjugates Allow Multitarget Therapy of Triple Negative Breast Cancer.
    Colombo M; Rizzuto MA; Pacini C; Pandolfi L; Bonizzi A; Truffi M; Monieri M; Catrambone F; Giustra M; Garbujo S; Fiandra L; Corsi F; Prosperi D; Mazzucchelli S
    Bioconjug Chem; 2018 Nov; 29(11):3817-3832. PubMed ID: 30350574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
    Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
    Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
    Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
    You KS; Yi YW; Kwak SJ; Seong YS
    Int J Oncol; 2018 Mar; 52(3):828-840. PubMed ID: 29344641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells.
    Tanei T; Choi DS; Rodriguez AA; Liang DH; Dobrolecki L; Ghosh M; Landis MD; Chang JC
    Breast Cancer Res; 2016 Jan; 18(1):6. PubMed ID: 26757880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.
    Sartore-Bianchi A; Martini M; Molinari F; Veronese S; Nichelatti M; Artale S; Di Nicolantonio F; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    Cancer Res; 2009 Mar; 69(5):1851-7. PubMed ID: 19223544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy.
    Lin JK; Lin AJ; Lin CC; Lan YT; Yang SH; Li AF; Chang SC
    J Surg Oncol; 2011 Nov; 104(6):661-6. PubMed ID: 21671463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells.
    Nakai K; Xia W; Liao HW; Saito M; Hung MC; Yamaguchi H
    Breast Cancer; 2018 Jan; 25(1):74-80. PubMed ID: 28643125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].
    Fabian P; Berkovcová J
    Cesk Patol; 2011 Oct; 47(4):154-8. PubMed ID: 22145213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
    Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A
    J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.